Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for treating peritoneal fibrosis

A dialysate and solution technology, applied in the field of dialysate, treatment, prevention or reduction of peritoneal fibrosis, can solve the problems of reduced PD efficiency and treatment strategies that have not been fully developed

Active Publication Date: 2014-06-04
VETERANS GEN HOSPITAL TAIPEI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, these chronically inflamed sites are associated with progressive peritoneal angiogenesis [16-19] , which eventually leads to a decrease in PD efficiency
However, therapeutic strategies targeting this pathogenic process have not been fully developed [17]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating peritoneal fibrosis
  • Method for treating peritoneal fibrosis
  • Method for treating peritoneal fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0066] I. Materials and methods

[0067] 1. Animal model and tissue preparation

[0068] All animal experiments were performed in accordance with the specifications of the Animal Experiment Committee of Taipei Veterans General Hospital. Five-week-old male Sprague-Dawley (SD) rats were purchased from the Experimental Animal Center of National Yang Ming University. Peritoneal dialysate (PDF) is based on Hirahara et al. [10；22] Prepared in the described manner, which contains 2.5% glucose, 100mmol / L NaCl, 35mmol / L sodium lactate, 2mmol / L CaCl 2 , and 0.7mmol / L MgCl 2 , the pH value is 5.0. To test MGO efficacy, PDF containing 0, 3, 6, 12 mM MGO (Sigma, St. Louis, MO, USA) was intraperitoneally injected at a dose of 50 mL per kg for 10 consecutive days. Dimethyl sulfoxide (DMSO, dimethyl sulfoxide) (Sigma, St. Louis, MO, USA) was used as a solvent for MGO. To explore the efficacy of CBR ligands, SD rats were treated with selective CB 1 R antagonist, AM281 (Alexis Biochemica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treating, preventing or reducing peritoneal fibrosis comprising administering to a subject in need thereof a pharmacologically effective dose of a type I cannabinoid receptor (CB1R) antagonist or a type II cannabinoid receptor (CB2R) agonist. Also provided is a dialysis fluid for treating, preventing or reducing peritoneal fibrosis comprising electrolytes, an osmotic agent, a physiologically acceptable pH solution, and a pharmacologically effective dose of a CB1R antagonist or a CB2R agonist.

Description

[0001] Related applications [0002] This application claims priority from US Provisional Patent Application No. 61 / 729,170 (filing date: November 21, 2012), the entire contents of which are hereby incorporated by reference. technical field [0003] The invention relates to a dialysate for treating, preventing or reducing fibrosis, in particular to a dialysate for treating, preventing or reducing peritoneal fibrosis. It belongs to the field of medicine for treating diseases. Background technique [0004] Lifelong peritoneal dialysis (PD, peritoneal dialysis) is a renal replacement therapy whose use is limited by peritoneal fibrosis. Several studies have shown that hypertonic glucose solutions are not only toxic to mesothelial cells [1；2] , can also promote the apoptosis of immune cells [3] . In addition, the high temperature sterilization process will produce glucose degradation products (GDPs, glucose degradation products) such as methylglyoxal (MGO, methylglyoxal), ace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P7/08A61P43/00A61K31/454A61K31/343A61K31/5377A61K31/352
CPCA61K31/454A61K31/5377A61P7/08A61P43/00
Inventor 杨智宇杨安航
Owner VETERANS GEN HOSPITAL TAIPEI